Skip to content
    UNH
    Earnings call· Mar 2026(Q1 FY26)

    UNITEDHEALTH GROUP Q1 FY26 earnings call UNH

    Apr 21, 2026 Source

    Executive summary

    UnitedHealth Group Q1 FY26 — Strong Start with AI Investments and OptumHealth Turnaround

    UnitedHealth Group delivered a strong financial performance in the first quarter, driven by improving fundamentals across all segments, notably OptumHealth's operational turnaround and disciplined pricing in UnitedHealthcare. The company is making significant investments in AI to modernize operations and enhance customer experience, while also refocusing on core U.S. healthcare businesses and strengthening corporate governance.

    Highlights

    5
    • Adjusted earnings per share of $7.23, well ahead of expectations.

    • Total revenues grew 2% year-over-year to $111.7 billion.

    • Medical care ratio improved to 83.9% from 84.8% in Q1 2025.

    • Operating cash flows reached $8.9 billion, representing 1.4x net income.

    • Debt to capital ratio reduced to 42.9%, on track for the year-end goal of 40%.

    Concerns

    3
    • Medicaid membership attrition and negative margins are expected in 2026 due to high trend and insufficient funding.

    • The individual ACA business is projected to see total membership decline by approximately 1/3 in 2026.

    • Medicare Advantage medical trends remain elevated, consistent with levels seen exiting 2025.

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year Adjusted EPS
    greater than $18.25 per share
    high materiality
    High
    OptumHealth long-term sustainable margin levels
    6% to 8%
    medium materiality
    High
    Medicare Advantage margin advance
    50 basis point year-over-year advance
    medium materiality
    High
    Medicare Advantage long-term margin range
    upper half of the 2% to 4% long-term range
    medium materiality
    Medium
    Share repurchases
    at least $2 billion
    high materiality
    High
    AI-related initiatives investment
    nearly $1.5 billion
    medium materiality
    High
    Reduction in overall medical prior authorizations
    30% or more
    medium materiality
    High
    OptumInsight AI programs return
    conservatively 2:1
    medium materiality
    Medium
    Affordability delivered by OptumRx programs
    more than $1.5 billion
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    UnitedHealthcare
    Actions initiated last year are driving early momentum. Historical care utilization trends consistent with expectations. Medicaid membership attrition and negative margins expected in 2026, with modest improvements in 2027. Individual ACA business expected to contract by approximately 1/3 in 2026.
    Medicare & Retirement: disciplined pricing, strengthened by affordability initiativesCommunity & State: pressures in state-based rate environments, within expected rangeCommercial and ACA: consistent with pricing and trend assumptionsMedicare Advantage: 50 bps year-over-year margin advance expected for 2026Medicare Advantage: aspiration to be in upper half of 2% to 4% long-term range for 2027
    OptumHealth
    Positive Q1 results reflect strengthened operations, pricing, and operational improvements. Efforts focused on management and process improvements to steadily improve margins in 2026 and accelerate into 2027. Seasonality now resembles risk business, with significant majority of earnings in H1.
    Patients served in care models: over 20 millionPatients in fully value-based arrangements: over 4 millionWest region skilled nursing admissions reduction: 35% in first month compared to last yearPatient facing hours increase: 12% year-over-yearLong-term sustainable margin levels: 6% to 8%
    $1.3 billion adjusted earnings
    OptumRx
    Started the year by onboarding new clients and reducing call center volume through digital and AI-enabled self-service. Utilization and drug cost trends were as expected, with scripts down slightly. More naturally weighted to back half, with approximately 60% of earnings in H2.
    New clients onboarded: 800+Contact call center volume reduction: 25%Precheck prior authorization approval time: under 30 seconds (from 8+ hours)Precheck prior authorization denial reduction: 68%Precheck prior authorization appeals reduction: 88%Member satisfaction: over 95%
    OptumInsight
    New AI-first products gaining traction, helping payers and care providers with administrative functions. Optum Financial Services agreed to acquire Alegeus Technologies, expected to be accretive in 2027. More naturally weighted to back half, with approximately 60% of earnings in H2.
    Optum Real transactions: 0.5 billion year-to-dateOptum Real projected transactions: over 2.5 billion for the yearManual contact costs reduction (Optum Real): 76%Digital prior auth approval rate on first submissions: 96%

    Operational metrics

    18
    Adjusted earnings per share
    $7.23well ahead of expectations
    Q1 FY26
    Medical care ratio (MCR)
    83.9%vs 84.8% in Q1 2025
    Q1 FY26
    Operating cost ratio
    13.8%
    Q1 FY26

    reflecting timing of targeted investments and incentive compensation

    Debt to capital ratio
    42.9%on track to year-end goal of 40%
    Q1 FY26
    Incentive compensation
    $900 millionvs $35 million in Q1 2025
    Q1 FY26
    Net negative impact of restructuring actions
    $50 million
    Q1 FY26

    excluded from adjusted earnings per share

    Gain on sale of U.K. business
    $525 million
    Q1 FY26

    used $400 million to fund UnitedHealth Foundation

    Total revenues growth
    2%year-over-year
    Q1 FY26
    Total domestic members
    49.1 millionvs 49.8 million at end of 2025
    Q1 FY26
    Digital visits (UHC)
    73 millionup 42% over last 2 years
    Q1 FY26
    Digital access adoption (UHC)
    almost half
    Q1 FY26

    registered for and using UHC digital access

    Consumer contacts via digital formats
    over 80%
    Q1 FY26

    primary way members interact

    Provider portal/API usage
    about 75%
    Q1 FY26
    Prior authorization requests submitted electronically
    nearly 95%
    Q1 FY26
    Prior authorization requests processed in real time
    about 50%
    Q1 FY26
    Prior authorization requests approved in one business day
    more than 90%
    Q1 FY26
    OptumHealth settings with new standards
    nearly 70%
    Q1 FY26
    Prior-year reserve development (net)
    a little bit north of $500 million
    Q1 FY26

    benefits the quarter, prudent view at March 31

    Industry KPIs

    10
    MetricValueDetails
    Utilization trendselevated high levels
    Stars rate environmentupper half of 2% to 4% long-term range%
    Medical loss care ratio83.9%%
    Client retention new wins800+clients
    Pharmacy scripts specialtydown slightly
    Membership covered lives by line49.1 millionmembers
    Prior year reserve development pdra little bit north of $500 millionUSD
    Adjusted EPS EBITDA leverage guidancegreater than $18.25USD
    Prior authorization operational metricsnearly 95%%
    Medical cost trend vs pricing assumptionelevated but stable

    Deals & partnerships

    1
    Alegeus Technologiesacquisition

    Optum Financial Services agreed to acquire Alegeus Technologies, a leading health financial services business, to provide more flexible consumer-centered solutions.

    Risks & headwinds

    5
    Pressures in state-based rate environments for Community & State (Medicaid)2026, with modest margin improvements beginning in 2027

    membership attrition and negative margins in 2026

    Mitigation: Advocating with state partners for appropriate rate alignment, disciplined cost management, operational efficiencies, intensifying work to address fraud/waste/abuse.

    Contracting individual ACA business2026

    total membership to decline by approximately 1/3 in 2026

    Mitigation: Focus on bronze and gold-tiered products where member mix and utilization align with plan; pledge to refund any 2026 profits from these plans.

    Elevated Medicare Advantage medical trends2026

    elevated, but in line with our pricing assumptions

    Mitigation: Disciplined pricing, product positioning towards HMO-based products, better tools to identify outlier patterns, clinical programs, pain integrity programs, network actions.

    PBM legislation (e.g., in Tennessee)Current

    will harm access for nearly 150,000 Tennesseans with complex conditions

    Mitigation: Advocating for patients in Tennessee and elsewhere; leading on independent pharmacy stability, consumer affordability (Price Edge, specialty savings IQ), patient/provider experience (PreCheck my prior auth), and payer transparency.

    Medical trend for 2027 still meaningfully above funding levels for Medicare Advantage2027

    expected medical trend for 2027 is still meaningfully above these funding levels

    Mitigation: Focus on financial sustainability, product durability, and path to margin recovery (2% to 4% long-term range).

    Q&A highlights

    8

    Clarify if MA cost trend is running closer to the 7-8% historical range or the 10% pricing assumption, and identify areas of acceleration or moderation.

    Tim Noel stated that overall trend is progressing in line with expectations, with modest favorability in government programs (including MA). Utilization patterns remain at elevated 2025 levels, with no inflection point, and the company is comfortable with its 10% pricing assumption for 2026.

    We're seeing some modest favorability in the government programs which would then include Medicare Advantage, commercial very consistent with from those expectations. It's really early right now.

    asked by Albert Rice · answered by Timothy Noel

    2 min read6 chapters

    Detailed Narrative

    01

    AI-First Strategy and Investments

    UnitedHealth Group is investing nearly $1.5 billion in AI-related initiatives in 2026, aiming for a conservative 2:1 return on these programs over the next few years, with many paying back within 12 to 18 months. These investments are focused on modernizing core processes, improving consumer and provider experiences, and enhancing productivity. OptumInsight is leading the commercialization of AI-first products, such as Digital prior auth, which shows a 96% approval rate on first submissions, and Optum Real, which is projected to handle over 2.5 billion transactions this year.

    02

    OptumHealth Turnaround and Operational Improvements

    OptumHealth reported adjusted earnings of $1.3 billion, reflecting significant pricing and operational improvements initiated in late 2025. These include favorable medical trends from prior periods, particularly in markets with focused clinical and medical management efforts, and a 12% year-over-year increase in patient-facing hours. The segment is returning to a disciplined, integrated value-based care model, with efforts in regions like the West leading to a 35% reduction in skilled nursing admissions in the first month compared to last year. The long-term sustainable margin target for OptumHealth is 6% to 8%.

    03

    UnitedHealthcare Performance and Medicaid Challenges

    UnitedHealthcare's results demonstrate disciplined pricing and affordability initiatives, with medical trends largely consistent with expectations. However, the Community & State segment (Medicaid) continues to face pressures from high trends and insufficient funding, leading to an expected membership attrition and negative margins in 2026, with modest improvements anticipated in 2027. The individual ACA business is also expected to contract, with total membership declining by approximately 1/3 in 2026, though the company pledges to refund any profits from these plans.

    04

    PBM Legislation and Transparency Leadership

    OptumRx has accounted for the impacts of PBM legislation in its guidance and is positioned as a leader in industry transparency, offering a 15-part guarantee for clients. The company is actively addressing concerns about state-level legislation, such as in Tennessee, which could harm access for nearly 150,000 Tennesseans with complex conditions. OptumRx is also focused on ensuring independent pharmacy stability, enhancing consumer affordability through programs like Price Edge, and improving patient/provider experience with tools like PreCheck my prior auth.

    05

    Capital Allocation and Balance Sheet Strength

    UnitedHealth Group has strengthened its balance sheet, reducing its debt to capital ratio to 42.9%, on track for a year-end goal of 40%. The company initiated share repurchases earlier than anticipated, expecting to deploy at least $2 billion by the end of Q2, reflecting confidence in its results and the perceived intrinsic value discount of its shares. Strategic acquisitions that support long-term growth remain a priority, managed with prudence.

    06

    Governance and Community Engagement

    The company has enhanced its corporate governance by establishing a public responsibility committee of the Board, appointing a new lead independent director, and accelerating its Board recruiting process. UnitedHealth Group has also renewed its commitment to community engagement, providing additional resources to the UnitedHealth Foundation and expanding its focus on improving rural healthcare, strengthening the healthcare workforce, and addressing maternal and children's health.

    AI-generated summary of the company’s earnings call. Not investment advice.